World TB day 2023 - iM4TB announces major progress in macozinone development and new partnership with Resistell
The @Innovative Medicines for Tuberculosis (iM4TB) foundation, a Swiss non-profit fighting tuberculosis (TB), is pleased to announce a new partnership with @Resistell. The partners will harness Resistell’s proprietary Phenotech technology to further investigate iM4TB’s TB drug candidate, macozinone (PBTZ169).
Macozinone successfully completed phase 1a, b clinical trials at the @CHUV (Centre Hospitalier Universitaire Vaudois) in Lausanne and is now undergoing further formulation for phase 2 trials. To advance this work and better understand macozinone’s bactericidal properties, Resistell’s phenotech device, employing nanomotion technology, is being employed.
“We are honoured to collaborate with iM4TB in this study and to help them in the development of a more effective and affordable treatment for tuberculosis,” said the CEO of Resistell, Danuta Cichocka.
Professor Stewart Cole, Chair of the iM4TB board, said that “it is great to see two EPFL spinoffs working together to tackle tuberculosis, the world’s leading killer. The Phenotech device will accelerate macozinone development by generating phenotypic data ten times faster than conventional methods.”
Work at iM4TB is supported by @BMGF (the Bill and Melinda Gates Foundation) and @ERA4TB (the European Regimen Accelerator for Tuberculosis), part of the European Commission’s Innovative Medicines Initiative to tackle antimicrobial resistance (AMR).
